Clinical Trial Goal
To find out if mosunetuzumab is safe and works well to treat indolent B-cell lymphoma that has not yet been treated
You may be able to join this trial if you:
- Are 18 years old or older
- Have indolent B-cell lymphoma that has not yet been treated
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Mosunetuzumab is a T-cell engaging bispecific antibody that target CD20 and CD3 on certain cells.
You’ll get:
You’ll get:
- Mosunetuzumab – Given as an intravenous (IV) infusion 1 time each week.
You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 5 years.
The Food and Drug Administration (FDA) has approved mosunetuzumab to treat B-cell lymphoma. Using it in this way to treat indolent B-cell lymphoma that has not yet been treated is new and unproven.
Locations
Fred Hutch/University of Washington Cancer ConsortiumRECRUITING
Seattle, Washington
Ajay Gopal, 206-606-2037, agopal@uw.edu
Sponsors
lead: University of Washington
